Infinitopes raises €13.9M Seed round
21 January 2026· Oxford, United Kingdom· biotechnology, oncology, ai, immunotherapy, software_hardware
The funding will support the launch of its first-in-human, double-blind, randomised, placebo-controlled clinical trial of ITOP1, a precision therapeutic vaccine aimed at preventing recurrence in oesophageal cancer. It will also enable proof-of-concept evaluation of Infinitopes' AI/ML-precision targeted, off-the-shelf vaccine platform.
Investors
LeadOctopus Ventures
Also participating
Amplify BioMacmillan Cancer SupportManta Ray VenturesCancer Research Horizons
About Infinitopes
Stage
Seed
Headquarters
Oxford, United Kingdom
Founded
2021
Team Size
6–20
Sectors
biotechnologyoncologyaiimmunotherapysoftware_hardware